Optimizing the use of colonoscopy for CRC screening in a large community-based
在大型社区中优化结肠镜检查在 CRC 筛查中的应用
基本信息
- 批准号:8567814
- 负责人:
- 金额:$ 58.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenomatous PolypsAfrican AmericanAgeAsian AmericansAttentionBehaviorBehavioralBiologicalCaliforniaCancer Intervention and Surveillance Modeling NetworkCarcinomaCessation of lifeCollaborationsColonoscopyColorectal CancerCommunitiesDataDatabasesDetectionDiagnosisEffectivenessFailureFamily PhysiciansFocus GroupsGastroenterologistGenetic MarkersGeographic LocationsGoalsGuidelinesHealth PersonnelHealthcareHealthcare SystemsHispanicsHumanIndividualInterventionInterviewIntestinesInvestigationLocationMalignant NeoplasmsMapsMeasuresMedicalMedical centerMethodsModalityModelingOncologistOpticsOrganizational ChangeOutcomePatientsPatternPerformancePersonsPhysiciansPolypectomyPolypsPopulationPreparationProcessProviderPublishingRaceRelative (related person)ResearchResearch PersonnelResourcesRiskScientistScreening ResultScreening for cancerSeriesSiteSystemTechniquesTestingTissuesVariantadenomabasebehavior changecancer diagnosiscancer riskcohortcolorectal cancer screeningcostdemographicsfollow-uphealth care deliveryhigh riskimprovedmemberpatient populationpopulation basedpreventprogramsscreeningsexsocioeconomicssuccesstheoriestool
项目摘要
The overall goal of the Research Center is the creation of a research unit that can evaluate the complete colorectal cancer (CRC) screening process. The specific goal is the characterization of remediable failures of the two most commonly used screening tests (optical colonoscopy and fecal immunochemical tests [FIT]). Two important problems in CRC are over-screening and under-diagnosis: 1) >95% of people will not die of CRC, thus, for most patients, screening results only in worry & risk; yet 2) many CRC deaths occur despite CRC screening (i.e. in persons with prior screening). It is unclear how many deaths result from remediable failures of the screening process. Our center will evaluate a community-based cohort that includes detailed CRC screening and medical data for >2 million screening-eligible people/year; >10 years of data; large numbers of outcomes (38,000 cancers); geographic diversity (>35 medical centers across California); demographic diversity (140,000 African Americans, 320,000 Hispanics, and 200,000 Asian-Americans among current members); socioeconomic diversity; diversity of screening methods; access to tissue/cancer blocks; and a full spectrum of individual cancer risk. Project 1 will evaluate FIT, an effective and efficient noninvasive screening method. Project 2 will evaluate colonoscopy, a sensitive, widely used test that is the final common exam for all CRC screening strategies. Projects 1 & 2 will both evaluate patterns of use, especially: screening failures (cancers diagnosed despite screening); surveillance failures, and surveillance over-use. We will investigate physician and patient components for these failures using a recently developed systematic process that includes establishing bases for interventions that target barriers in healthcare settings. Project 1 will also evaluate clinically available genetic markers to evaluate for potential biological differences between FIT detected vs. screen failure cancers. Project 3 will model the effectiveness of colonoscopy vs. FIT utilizing community-based data from the full screening process acquired in Projects 1 & 2, in collaboration with a proven NCI consortium Cancer Intervention and Surveillance Modeling Network (CISNET) site, including different screening strategies for different patient populations, tailored to risk. The Center includes a trans-disciplinary group of researchers including gastroenterologists, oncologists, family physicians, population scientists, modeling experts, quality experts, behavioral experts, and experts in health care delivery. The Center can efficiently evaluate the full screening process and can provide substantial human, institutional, and patient resources for collaborative projects within the PROSPR network.
研究中心的总体目标是建立一个研究单位,可以评估完整的结直肠癌(CRC)筛查过程。具体目标是表征两种最常用的筛查试验(光学结肠镜检查和粪便免疫化学试验[FIT])的可补救失败。CRC的两个重要问题是过度筛查和诊断不足:1)>95%的人不会死于CRC,因此,对于大多数患者来说,筛查只会导致担忧和风险;然而2)尽管进行了CRC筛查,仍有许多CRC死亡(即在先前进行筛查的人中)。目前还不清楚有多少死亡是由于筛查过程中可补救的失败造成的。我们的中心将评估一个以社区为基础的队列,包括详细的CRC筛查和医疗数据,每年有超过200万筛查合格人群; >10年的数据;大量的结果(38,000例癌症);地理多样性(加州有超过35个医疗中心);人口统计学多样性(现有成员中有140,000名非洲裔美国人,320,000名西班牙裔美国人和200,000名亚裔美国人);社会经济多样性;筛查方法的多样性;获得组织/癌症块;和个体癌症风险的全方位。项目1将评估FIT,一种有效和高效的非侵入性筛查方法。项目2将评估结肠镜检查,这是一种敏感的,广泛使用的测试,是所有CRC筛查策略的最终常见检查。项目1和2将评估使用模式,特别是:筛查失败(尽管筛查仍诊断出癌症);监测失败和监测过度使用。我们将使用最近开发的系统过程,包括建立基础的干预措施,在医疗环境中的目标障碍,调查这些故障的医生和患者组件。项目1还将评价临床可用的遗传标记物,以评价FIT检测与筛查失败癌症之间的潜在生物学差异。项目3将利用项目1和2中获得的基于社区的全面筛查过程数据,与经过验证的NCI联盟癌症干预和监测建模网络(CISNET)网站合作,对结肠镜检查与FIT的有效性进行建模,包括针对不同患者人群的不同筛查策略,针对风险量身定制。该中心包括一个跨学科的研究小组,包括胃肠病学家,肿瘤学家,家庭医生,人口科学家,建模专家,质量专家,行为专家和医疗保健专家。该中心可以有效地评估整个筛查过程,并为PROSPR网络内的合作项目提供大量的人力、机构和患者资源。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DOUGLAS Allen CORLEY其他文献
DOUGLAS Allen CORLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DOUGLAS Allen CORLEY', 18)}}的其他基金
Addressing Disparities in Outcomes of Screening for Colorectal Cancer in Community-Based Settings
解决社区环境中结直肠癌筛查结果的差异
- 批准号:
10682099 - 财政年份:2023
- 资助金额:
$ 58.49万 - 项目类别:
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)
优化社区人群的结直肠癌筛查精度和结果 (PRECISE)
- 批准号:
10394889 - 财政年份:2018
- 资助金额:
$ 58.49万 - 项目类别:
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)
优化社区人群的结直肠癌筛查精度和结果 (PRECISE)
- 批准号:
9906181 - 财政年份:2018
- 资助金额:
$ 58.49万 - 项目类别:
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)
优化社区人群的结直肠癌筛查精度和结果 (PRECISE)
- 批准号:
10611337 - 财政年份:2018
- 资助金额:
$ 58.49万 - 项目类别:
Effectiveness of screening for colorectal cancer in average risk adults: Colonoscopy vs FIT
平均风险成人结直肠癌筛查的有效性:结肠镜检查与 FIT
- 批准号:
10132734 - 财政年份:2017
- 资助金额:
$ 58.49万 - 项目类别:
Comprehensive Colorectal Cancer Risk Prediction to Inform Personalized Screening
全面的结直肠癌风险预测为个性化筛查提供信息
- 批准号:
9237818 - 财政年份:2017
- 资助金额:
$ 58.49万 - 项目类别:
Comprehensive Colorectal Cancer Risk Prediction to Inform Personalized Screening
全面的结直肠癌风险预测为个性化筛查提供信息
- 批准号:
10603019 - 财政年份:2017
- 资助金额:
$ 58.49万 - 项目类别:
Effectiveness of screening for colorectal cancer in average risk adults: Colonoscopy vs FIT
平均风险成人结直肠癌筛查的有效性:结肠镜检查与 FIT
- 批准号:
9905394 - 财政年份:2017
- 资助金额:
$ 58.49万 - 项目类别:
Effectiveness of screening for colorectal cancer in average risk adults: Colonoscopy vs FIT
平均风险成人结直肠癌筛查的有效性:结肠镜检查与 FIT
- 批准号:
10026306 - 财政年份:2017
- 资助金额:
$ 58.49万 - 项目类别:
Optimizing Colonoscopy & Fecal Immunochemical Tests for Community-Based Screening
优化结肠镜检查
- 批准号:
8221787 - 财政年份:2011
- 资助金额:
$ 58.49万 - 项目类别:
相似海外基金
Interactions between diet, microbiome, genetics and epigentics in determining risk for adenomatous polyps
饮食、微生物组、遗传学和表观遗传学之间的相互作用在确定腺瘤性息肉的风险中
- 批准号:
nhmrc : GNT1129430 - 财政年份:2017
- 资助金额:
$ 58.49万 - 项目类别:
Early Career Fellowships
Interactions between diet, microbiome, genetics and epigentics in determining risk for adenomatous polyps
饮食、微生物组、遗传学和表观遗传学之间的相互作用在确定腺瘤性息肉的风险中
- 批准号:
nhmrc : 1129430 - 财政年份:2017
- 资助金额:
$ 58.49万 - 项目类别:
Early Career Fellowships
Cohort study for colorectal diminutive adenomatous polyps
结直肠小腺瘤性息肉队列研究
- 批准号:
23650632 - 财政年份:2011
- 资助金额:
$ 58.49万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
DFMO & SULINDAC TO DECREASE RATE OF RECURRENCE OF ADENOMATOUS POLYPS IN COLON
DFMO
- 批准号:
7603734 - 财政年份:2007
- 资助金额:
$ 58.49万 - 项目类别:
PH III TRIAL DFMO & SULDINAC- DECREASE RECURRENCE ADENOMATOUS POLYPS IN COLON
PH III 试验 DFMO
- 批准号:
7625879 - 财政年份:2007
- 资助金额:
$ 58.49万 - 项目类别:
DFMO & SULINDAC TO DECREASE RATE OF RECURRENCE OF ADENOMATOUS POLYPS IN COLON
DFMO
- 批准号:
7376554 - 财政年份:2006
- 资助金额:
$ 58.49万 - 项目类别:
DFMO & SULINDAC TO DECREASE RATE OF RECURRENCE OF ADENOMATOUS POLYPS IN COLON
DFMO
- 批准号:
7199878 - 财政年份:2005
- 资助金额:
$ 58.49万 - 项目类别:
Calcium, Vitamin D, and Markers of Adenomatous Polyps
钙、维生素 D 和腺瘤性息肉标志物
- 批准号:
6943335 - 财政年份:2005
- 资助金额:
$ 58.49万 - 项目类别:
Calcium, Vitamin D, and Markers of Adenomatous Polyps
钙、维生素 D 和腺瘤性息肉标志物
- 批准号:
7082974 - 财政年份:2005
- 资助金额:
$ 58.49万 - 项目类别:
DFMO & Sulindac to Decrease Rate of Recurrence of Adenomatous Polyps in Colon
DFMO
- 批准号:
7039849 - 财政年份:2004
- 资助金额:
$ 58.49万 - 项目类别: